Inozyme Pharma, Inc.

INZY

US45790W1080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:03:54 2024-04-29 am EDT			5-day change	1st Jan Change
4.495 ^USD	+1.24%		+2.28%	+5.40%

Apr. 08	Transcript : Inozyme Pharma, Inc. - Special Call
Apr. 08	Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	CI

Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Completeness Index

June 23, 2023 at 12:00 am EDT

Latest news about Inozyme Pharma, Inc.

Transcript : Inozyme Pharma, Inc. - Special Call	Apr. 08
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	Apr. 08	CI
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency	Mar. 26	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions	23-10-10	CI
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency	23-09-26	CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Insider Buy: Inozyme Pharma	23-08-04	MT
Sector Update: Health Care Stocks Rising Late Friday	23-07-28	MT
Sector Update: Health Care	23-07-28	MT
Inozyme Pharma Prices $60 Million Share Offering	23-07-28	MT
Sector Update: Health Care Stocks Declining Late Wednesday	23-07-26	MT
Sector Update: Health Care Stocks Falling Wednesday Afternoon	23-07-26	MT
Sector Update: Health Care	23-07-26	MT
Inozyme Pharma Updates INZ-701 Development Plan After Meetings With US, EU Regulators; Shares Drop	23-07-26	MT
Transcript : Inozyme Pharma, Inc. - Special Call	23-07-26
Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency	23-07-26	CI
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701	23-06-27	CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Comp Value Index	23-06-23	CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000 Index	23-06-23	CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 3000E Index	23-06-23	CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell Small Cap Completeness Index	23-06-23	CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2500 Index	23-06-23	CI
Inozyme Pharma, Inc.(NasdaqGS:INZY) added to Russell 2000 Index	23-06-23	CI

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Companyâs lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.44 USD

Average target price

20.33 USD

Spread / Average Target

+357.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOZYME PHARMA, INC.	+5.40%	275M
IQVIA HOLDINGS INC.	+2.03%	42.75B
LONZA GROUP AG	+47.75%	41.61B
MODERNA, INC.	+12.03%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.72%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.11%	18.12B
MEDPACE HOLDINGS, INC.	+30.55%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.14%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.11%	11B

Other Biotechnology & Medical Research